Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, if he will make an assessment of the potential effect of implementing the recommendations contained in NICE's evaluation consultation document, Asfotase alfa for treating paediatric-onset hypophosphatasia, published on 22 September 2016, on the outcomes of people living with that disease.

The National Institute for Health and Care Excellence (NICE) is an independent body and is evaluating the costs and benefits of asfotase alfa (Strensiq) for treating paediatric-onset hypophosphatasia to determine whether it can be recommended for national commissioning by NHS England.

NICE published its draft recommendations for consultation on 22 September 2016 and the closing date for comments was 13 October 2016. NICE’s independent Evaluation Committee will now consider the comments received in response to the consultation. NICE has not yet issued its final guidance on this treatment and its draft recommendations may change following consultation.